Articles By Anuja Singh
Did 2025 Expose the Breaking Point of America’s Health Care System?
New reflections from healthcare leaders highlight how events in 2025 revealed deep structural weaknesses in the U.S. health…
ByHow Is Senhwa Biosciences Using AI and Strategic Collaborations to Shape the Next Generation…
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device…
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for…
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal…
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Did 2025 Expose the Breaking Point of America’s Health Care System?
New reflections from healthcare leaders highlight how events in 2025 revealed deep structural weaknesses in the U.S. health…
How Is Senhwa Biosciences Using AI and Strategic Collaborations to Shape the Next Generation…
TAIPEI and SAN DIEGO — Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on first-in-class therapies for oncology,…
Will the European Commission’s New Health Policy Package Accelerate Biotech, AI, and Medical Device…
The European Commission has unveiled a new health policy package to strengthen innovation, competitiveness, and resilience across the…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for…
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal…
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…